COYA
Coya TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
COYA Profile
Coya Therapeutics, Inc.
A clinical-stage biotechnology company focused on developing proprietary new therapies to enhance regulatory T cell function
Life Science Tools and Services
--
12/29/2022
NASDAQ Stock Exchange
8
12-31
Common stock
5850 San Felipe St. Suite 500, Houston, TX 77057
--
Coya Therapeutics, Inc., was incorporated under the laws of the State of Delaware. The company is a clinical-stage biotechnology company focused on developing patented drugs to regulate the function of sex T cells. Tregs is a subset of T lymphocytes composed of CD4 + CD25 high hFOXP 3 + cells that inhibit inflammation. Tregs and their transcription factors are essential for maintaining homeostasis by regulating autoimmune and inflammatory responses and maintaining mammalian self-tolerance. Treg dysfunction is an important part of the pathophysiology of severe neurodegenerative diseases, autoimmune diseases and metabolic diseases, and the company believes that there is an urgent need for new and effective treatments.
